SYNH

Syneos HealthNasdaqGS:SYNH Stock Report

Market Cap

US$9.9b

7D

1.7%

1Y

83.6%

Updated

22 Sep, 2021

Data

Company Financials +
SYNH fundamental analysis
Snowflake Score
Valuation3/6
Future Growth3/6
Past Performance3/6
Financial Health3/6
Dividends0/6

SYNH Overview

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.

Syneos Health Competitors

IQVIA Holdings

NYSE:IQV

US$49.8b

Avantor

NYSE:AVTR

US$26.8b

Charles River Laboratories International

NYSE:CRL

US$22.5b

ICON

NasdaqGS:ICLR

US$21.9b

Price History & Performance

Summary of all time highs, changes and price drops for Syneos Health
Historical stock prices
Current Share PriceUS$95.28
52 Week HighUS$50.27
52 Week LowUS$97.48
Beta1.8
1 Month Change7.84%
3 Month Change10.39%
1 Year Change83.57%
3 Year Change91.13%
5 Year Change113.63%
Change since IPO365.01%

Recent News & Updates

Sep 02
When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

While Syneos Health, Inc. ( NASDAQ:SYNH ) might not be the most widely known stock at the moment, it saw a decent share...

Aug 18
Syneos Health (NASDAQ:SYNH) Has A Pretty Healthy Balance Sheet

Syneos Health (NASDAQ:SYNH) Has A Pretty Healthy Balance Sheet

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Aug 03
Calculating The Intrinsic Value Of Syneos Health, Inc. (NASDAQ:SYNH)

Calculating The Intrinsic Value Of Syneos Health, Inc. (NASDAQ:SYNH)

How far off is Syneos Health, Inc. ( NASDAQ:SYNH ) from its intrinsic value? Using the most recent financial data...

Shareholder Returns

SYNHUS Life SciencesUS Market
7D1.7%2.3%-1.7%
1Y83.6%58.3%36.2%

Return vs Industry: SYNH exceeded the US Life Sciences industry which returned 54.2% over the past year.

Return vs Market: SYNH exceeded the US Market which returned 31.5% over the past year.

Price Volatility

Is SYNH's price volatile compared to industry and market?
SYNH volatility
SYNH Beta1.8
Industry Beta0.97
Market Beta1

Stable Share Price: SYNH is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: SYNH's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201024,310Alistair Macdonaldhttps://www.syneoshealth.com

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process.

Syneos Health Fundamentals Summary

How do Syneos Health's earnings and revenue compare to its market cap?
SYNH fundamental statistics
Market CapUS$9.86b
Earnings (TTM)US$235.93m
Revenue (TTM)US$4.73b

41.8x

P/E Ratio

2.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SYNH income statement (TTM)
RevenueUS$4.73b
Cost of RevenueUS$3.61b
Gross ProfitUS$1.12b
ExpensesUS$888.38m
EarningsUS$235.93m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)2.27
Gross Margin23.77%
Net Profit Margin4.99%
Debt/Equity Ratio88.7%

How did SYNH perform over the long term?

See historical performance and comparison

Valuation

Is Syneos Health undervalued compared to its fair value and its price relative to the market?

11.8%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SYNH ($95.28) is trading below our estimate of fair value ($108.08)

Significantly Below Fair Value: SYNH is trading below fair value, but not by a significant amount.


Price To Earnings Ratio

PE vs Industry: SYNH is good value based on its PE Ratio (41.8x) compared to the US Life Sciences industry average (51.2x).

PE vs Market: SYNH is poor value based on its PE Ratio (41.8x) compared to the US market (17.5x).


Price to Earnings Growth Ratio

PEG Ratio: SYNH is poor value based on its PEG Ratio (2x)


Price to Book Ratio

PB vs Industry: SYNH is good value based on its PB Ratio (3x) compared to the US Life Sciences industry average (6.1x).


Future Growth

How is Syneos Health forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

20.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYNH's forecast earnings growth (20.9% per year) is above the savings rate (2%).

Earnings vs Market: SYNH's earnings (20.9% per year) are forecast to grow faster than the US market (14.9% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: SYNH's revenue (7.8% per year) is forecast to grow slower than the US market (9.8% per year).

High Growth Revenue: SYNH's revenue (7.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SYNH's Return on Equity is forecast to be low in 3 years time (15%).


Past Performance

How has Syneos Health performed over the past 5 years?

31.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SYNH has high quality earnings.

Growing Profit Margin: SYNH's current net profit margins (5%) are higher than last year (4.1%).


Past Earnings Growth Analysis

Earnings Trend: SYNH's earnings have grown significantly by 31.1% per year over the past 5 years.

Accelerating Growth: SYNH's earnings growth over the past year (25.9%) is below its 5-year average (31.1% per year).

Earnings vs Industry: SYNH earnings growth over the past year (25.9%) underperformed the Life Sciences industry 56.9%.


Return on Equity

High ROE: SYNH's Return on Equity (7.3%) is considered low.


Financial Health

How is Syneos Health's financial position?


Financial Position Analysis

Short Term Liabilities: SYNH's short term assets ($1.7B) exceed its short term liabilities ($1.6B).

Long Term Liabilities: SYNH's short term assets ($1.7B) do not cover its long term liabilities ($3.2B).


Debt to Equity History and Analysis

Debt Level: SYNH's debt to equity ratio (88.7%) is considered high.

Reducing Debt: SYNH's debt to equity ratio has reduced from 157.2% to 88.7% over the past 5 years.

Debt Coverage: SYNH's debt is not well covered by operating cash flow (16.9%).

Interest Coverage: SYNH's interest payments on its debt are well covered by EBIT (4.6x coverage).


Balance Sheet


Dividend

What is Syneos Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SYNH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SYNH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SYNH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SYNH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SYNH's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Alistair Macdonald (51 yo)

4.92yrs

Tenure

US$7,776,953

Compensation

Mr. Alistair Macdonald has been the Chief Executive Officer and Director of Syneos Health, Inc. (formerly, INC Research Holdings, Inc.) since October 1, 2016. Mr. Macdonald served as the Chief Operating Of...


CEO Compensation Analysis

Compensation vs Market: Alistair's total compensation ($USD7.78M) is below average for companies of similar size in the US market ($USD11.42M).

Compensation vs Earnings: Alistair's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: SYNH's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: SYNH's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Syneos Health, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Syneos Health, Inc.
  • Ticker: SYNH
  • Exchange: NasdaqGS
  • Founded: 2010
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$9.860b
  • Shares outstanding: 103.48m
  • Website: https://www.syneoshealth.com

Number of Employees


Location

  • Syneos Health, Inc.
  • 1030 Sync Street
  • Morrisville
  • North Carolina
  • 27560-5468
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/22 22:44
End of Day Share Price2021/09/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.